The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

International Journal of Molecular Sciences

Elena Ongaro¹  Alfredo Falcone¹  Chiara Cremolini¹  Carlotta Antoniotti¹ 

[1] Department of Oncology, University Hospital of Pisa, 56126 Pisa, Italy;

关键词: metastatic colorectal cancer;    biomarkers;    anti-EGFR agents;    primary resistance;    negative selection;   

DOI  :  10.3390/ijms19082298

来源: DOAJ

【 摘 要 】

In the evolving molecular landscape of metastatic colorectal cancer, optimizing available tools to select patients to receive anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies is a modern challenge of colorectal oncologists. Several molecular biomarkers have been investigated in recent years as potential predictors of resistance to anti-EGFR agents in preclinical and clinical retrospective series. Nevertheless, none of them have been implemented in clinical practice due to the lack of a formal prospective demonstration. Here, we propose a literature review of molecular alterations associated with resistance to anti-EGFRs, underlining the reasons why their roadmap from laboratories to clinics was prematurely halted.

【 授权许可】

Unknown